Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Depreciation & Amortization (CF) (2019 - 2025)

Avidity Biosciences' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 103.25% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $4.2 million, up 52.85%, while the annual FY2025 figure was $4.2 million, 51.3% up from the prior year.
  • Depreciation & Amortization (CF) reached $1.5 million in Q4 2025 per RNA's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.5 million in Q4 2025 to a low of $100000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $552950.0, with a median of $550000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): changed 0.0% in 2021, then soared 214.0% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $208000.0 in 2021, then surged by 92.31% to $400000.0 in 2022, then surged by 53.5% to $614000.0 in 2023, then rose by 20.2% to $738000.0 in 2024, then soared by 103.25% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Depreciation & Amortization (CF) are $1.5 million (Q4 2025), $1.1 million (Q3 2025), and $800000.0 (Q2 2025).